C
Charles A. Linker
Researcher at University of California, San Francisco
Publications - 100
Citations - 5524
Charles A. Linker is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Transplantation & Leukemia. The author has an hindex of 37, co-authored 100 publications receiving 5224 citations. Previous affiliations of Charles A. Linker include City of Hope National Medical Center & Stanford University.
Papers
More filters
Journal ArticleDOI
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy,Kouros Owzar,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Paul G. Richardson,Sergio Giralt,Edward A. Stadtmauer,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas G. Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Robert L. Schlossman,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Seiler,Cara A. Rosenbaum,Parameswaran Hari,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Kenneth C. Anderson,Charles A. Linker +39 more
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Journal ArticleDOI
Fungal infections in patients with acute leukemia.
TL;DR: Suggests are made for improved management of patients at high risk for invasive fungal infections in patients undergoing intensive induction chemotherapy, based upon recognition of the clinical settings in whichfungal infections occur and the aggressive use of invasive diagnostic procedures.
Journal ArticleDOI
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
Richard A. Larson,Richard K. Dodge,Charles A. Linker,Richard Stone,Bayard L. Powell,Edward J. Lee,Philip Schulman,Frederick R. Davey,Stanley R. Frankel,Clara D. Bloomfield,Stephen L. George,Charles A. Schiffer +11 more
TL;DR: Children and adults with untreated ALL who received intensive chemotherapy for ALL benefited from G-CSF treatment, but its use did not markedly affect the ultimate outcome.
Journal ArticleDOI
Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma
Sara Gonias,Robert E. Goldsby,Katherine K. Matthay,Randall A. Hawkins,David H. Price,John P. Huberty,Lloyd E. Damon,Charles A. Linker,Aimee Sznewajs,Steve Shiboski,P. A. Fitzgerald +10 more
TL;DR: Although serious toxicity may occur, the survival and response rates achieved with high-dose [(131)I]MIBG suggest its utility in the management of selected patients with metastatic PHEO and PGL.
Journal ArticleDOI
Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia
TL;DR: Intensified and shortened chemotherapy may improve the outcome for patients with ALL with B-precursor disease lacking high-risk features, and further trials of this regimen are warranted.